OTLK Outlook Therapeutics

Outlook Therapeutics Announces Initiation of Supplemental Open-Label Safety Study for ONS-5010 / LYTENAVA™ (bevacizumab-vikg)

Outlook Therapeutics Announces Initiation of Supplemental Open-Label Safety Study for ONS-5010 / LYTENAVA™ (bevacizumab-vikg)
EN
13/10/2020

Underlying

OTLKOutlook Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Outlook Therapeutics

 PRESS RELEASE
Free
OTLK Outlook Therape...

Outlook Therapeutics Announces Closing of $5.0 Million Public Offering

Outlook Therapeutics Announces Closing of $5.0 Million Public Offering ISELIN, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the closing of its previously announced public offering of 20,000,000 shares of its common stock and accompanying warrants to purchase up to an aggregate of 20,000,000 shares of common stock. Each share of common stock and accompanying common warrant were sold together at a combined public offering price of $0.25. Ea...

March 25, 2026 1 EN
 PRESS RELEASE
Free
OTLK Outlook Therape...

Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering

Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering ISELIN, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the pricing of its previously announced public offering of 20,000,000 shares of its common stock and accompanying warrants to purchase up to an aggregate of 20,000,000 shares of common stock. Each share of common stock and accompanying common warrant are being sold together at a combined public offering price of $0.2...

March 24, 2026 1 EN
 PRESS RELEASE
Free
OTLK Outlook Therape...

Outlook Therapeutics Announces Proposed Public Offering

Outlook Therapeutics Announces Proposed Public Offering ISELIN, N.J., March 23, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has commenced a best-efforts public offering of its common stock (or pre-funded warrants in lieu thereof) and accompanying warrants exercisable for shares of its common stock. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to th...

March 23, 2026 1 EN
 PRESS RELEASE
Free
OTLK Outlook Therape...

Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note ...

Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note ISELIN, N.J., March 16, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced an amendment to its existing convertible note with Avondale Capital, LLC (the “Existing Note”) and the issuance of a new non-convertible, unsecured note with Atlas Sciences, LLC (the “New Note”). Under the amendment to the Existing Note, the maturity date of the Ex...

March 16, 2026 1 EN
 PRESS RELEASE
Free
OTLK Outlook Therape...

Outlook Therapeutics Provides Update Following Type A Meeting with FDA...

Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg) ISELIN, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today provided an update following its recent Type A meeting with the U.S. Food and Drug Administration (FDA) to discuss the December 30, 2025 Complete Response Letter (CRL) for the Biologics License Application (BLA) for ONS-5010/LYTENAVA™ (bevacizumab-vikg). The Type A meeting was c...

March 5, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch